• Editas Medicine presented preclinical EDIT-401 data at the European Atherosclerosis Society Congress on May 25, 2026.
• The single-dose gene-editing candidate produced broad, rapid reductions across key atherogenic lipoproteins in non-human primates.
• The program remains preclinical, with a first-in-human study planned in Australia later in 2026 for heterozygous familial hypercholesterolemia.
• Editas targets a mid-2026 Clinical Trial Notification filing, with early in vivo human proof-of-concept data expected by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260601PRIMZONEFULLFEED9726156) on May 26, 2026, and is solely responsible for the information contained therein.